Lynx1 Capital Management LP Cullinan Oncology, Inc. Transaction History
Lynx1 Capital Management LP
- $257 Million
- Q4 2024
A detailed history of Lynx1 Capital Management LP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 1,257,795 shares of CGEM stock, worth $10.7 Million. This represents 5.95% of its overall portfolio holdings.
Number of Shares
1,257,795
Previous 410,830
206.16%
Holding current value
$10.7 Million
Previous $6.88 Million
122.76%
% of portfolio
5.95%
Previous 2.46%
Shares
4 transactions
Others Institutions Holding CGEM
# of Institutions
153Shares Held
67.1MCall Options Held
41.1KPut Options Held
112K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$64.9 Million13.93% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$48.8 Million2.62% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$30.1 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$29 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.38MShares$28.7 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $387M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...